FDA granted Fast Track Designation for 2L Acute Myeloid Leukaemia (AML) High Impact oral presentation of 2L NSCLC clinical data at SITC Met primary and secondary endpoints in non-small cell lung cancer (NSCLC) Phase II clinical trial in patients previously treated with chemotherapy...
